Core Insights - Bavarian Nordic A/S reported preliminary financial results for 2025, with revenue of DKK 6,244 million, exceeding the latest guidance of approximately DKK 6,000 million [1][2] - The company achieved an EBITDA of DKK 2,542 million, resulting in an EBITDA margin of 41%, surpassing the latest guidance of approximately 40% [2][4] Financial Performance - Revenue breakdown for 2025 includes DKK 3,105 million from Public Preparedness and DKK 2,963 million from Travel Health, with Travel Health showing a 30% year-over-year growth [5][7] - The company’s core vaccines, rabies and TBE, contributed significantly to the revenue growth, with respective increases of 34% and 20% [5] - The chikungunya vaccine generated DKK 85 million in its first year of sales, exceeding guidance by DKK 10 million [5] 2026 Financial Guidance - For 2026, Bavarian Nordic expects revenue between DKK 5,000 million and DKK 5,200 million, with an EBITDA margin of approximately 25% [6][7] - Revenue from Public Preparedness is anticipated to be between DKK 1,800 million and DKK 2,000 million, with DKK 1,300 million already secured through contracts [8] - Travel Health revenue is projected at approximately DKK 3,000 million, reflecting a 10% growth over the prior year [9][10] Research and Development - R&D spending for 2026 is capped at DKK 750 million, focusing on life-cycle management of the commercial portfolio and additional studies for the chikungunya vaccine [11] - Early-stage pipeline assets are expected to enter clinical development in 2027 [11] Capital Expenditure - CAPEX for 2026 is expected to be around DKK 250 million, with inventory levels anticipated to remain relatively unchanged [12]

NerdWallet Announces Conference Call to Review 2025 Fourth Quarter and Full-Year Financial ResultsFeb 4, 2026 6:00 PM Eastern Standard Time# NerdWallet Announces Conference Call to Review 2025 Fourth Quarter and Full-Year Financial ResultsShare---SAN FRANCISCO--([BUSINESS WIRE])-- [NerdWallet], Inc. (NASDAQ: NRDS), which provides trustworthy financial guidance to consumers and small and mid-sized businesses (SMBs), today announced that it will release its fourth quarter and full-year 2025 financial results ...

Barrington raised the firm’s price target on Cimpress (CMPR) to $95 from $83 and keeps an Outperform rating on the shares after the company reported “solid” Q2 results and raised its FY26 guidance. Cimpress reiterated its target for adjusted EBITDA of at least $600M in FY28, the analyst noted. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Read More on CMPR: Disclaimer & DisclosureReport an Issue ...

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceFeb 3, 2026 6:45 AM Eastern Standard Time# Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 GuidanceShare---- Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026- Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline- Focused Execution Drives Strong Full-Year 2025 EPS PerformanceNEW YORK--([BUSINESS WIRE])--Pfizer Inc. (NYSE: PFE) reported financial results fo ...

Core Insights - Pharming Group N.V. has announced its financial guidance for 2026, projecting total revenues between US$405 million and US$425 million, representing an 8% to 13% growth [3][7][8] - The company will highlight its advancing clinical-stage pipeline, focusing on two major programs targeting primary immunodeficiencies and mitochondrial diseases during its Investor Day [2][4][6] Financial Guidance - Total revenue guidance for 2026 is set between US$405 million and US$425 million, driven by growth in its commercial products [3][8] - Total operating expenses are expected to be between US$330 million and US$335 million, primarily due to increased R&D expenses related to ongoing clinical trials [7][8] Pipeline Overview - Leniolisib is being developed for primary immunodeficiencies with immune dysregulation, with ongoing Phase II trials expected to yield top-line data in the second half of 2026 [4][5] - Napazimone (KL1333) is being developed for mtDNA-driven mitochondrial disease, with a pivotal clinical trial ongoing and results anticipated in 2027 [6][9] Clinical Programs - Leniolisib is currently approved as Joenja in the U.S. and is the first targeted treatment for activated PI3Kδ syndrome, with potential applicability across broader patient populations [5][6] - Napazimone (KL1333) aims to become the first standard of care for mtDNA-driven mitochondrial disease, addressing significant unmet medical needs [6][9] Investor Day Details - The Investor Day will feature presentations from clinical experts discussing disease biology and the potential impact of Pharming's programs [10][16] - The event is scheduled for February 3, 2026, from 10:00 a.m. to 12:00 p.m. EST, and will be available via webcast [11]

Core Insights - ANI Pharmaceuticals' shares have increased by 7% in the past week due to the positive financial guidance for 2026 that exceeded Wall Street expectations [1] Financial Guidance - The company anticipates 2026 sales between $1.055 billion and $1.115 billion, with EPS projected between $8.83 and $9.34, indicating a sales growth of 24-28% and earnings growth of 20-22% compared to 2025 guidance [2] - Approximately 60% of the expected 2026 revenues will come from the rare disease portfolio, with the remainder from the generics business [2] 2025 Preliminary Revenues - For 2025, Cortrophin Gel generated $347.8 million in sales, reflecting a 76% year-over-year growth, while the recently acquired ophthalmology assets, Iluvien and Yutiq, contributed $74.9 million [3] - Both figures align with ANI Pharmaceuticals' previously issued guidance [3] Growth Expectations - The company expects Cortrophin Gel sales in 2026 to be between $540 million and $575 million, representing a 55-65% increase over 2025 sales figures [4] - Sales growth is attributed to increased demand across various specialties and an expanded sales force [4] - Iluvien and Yutiq are expected to return to growth in 2026, with projected sales between $78 million and $83 million, up 4-11% from 2025 levels [5] Competitive Landscape - ANI Pharmaceuticals faces competition in its rare disease portfolio, particularly from AbbVie and Regeneron, which market established products that compete with Iluvien and Yutiq [6] - The primary competitor for Cortrophin Gel is Acthar Gel, marketed by Keenova Therapeutics, which has also raised its sales outlook for 2025 [7] Valuation and Performance - ANI Pharmaceuticals' shares have outperformed the industry year to date [8] - The stock is currently trading at a price/sales (P/S) ratio of 2.17, lower than the industry average of 2.47 [10] - EPS estimates for 2026 have increased over the past 30 days, while those for 2025 have declined [12]

Core Insights - Pfizer Inc. has provided its full-year 2026 revenue guidance, projecting revenues between $59.5 billion and $62.5 billion, while revising its 2025 revenue guidance to approximately $62.0 billion from a previous range of $61.0 billion to $64.0 billion [2][5] - The 2026 revenue guidance reflects an expected decrease of approximately $1.5 billion from COVID-19 products compared to 2025, along with a similar negative impact due to loss of exclusivity for certain products [2][11] - Pfizer anticipates operational revenue growth of about 4% year-over-year at the midpoint for 2026, excluding COVID-19 and loss of exclusivity products [2] Financial Guidance for 2026 - Adjusted Selling, Informational & Administrative (SI&A) expenses are expected to be between $12.5 billion and $13.5 billion, while Adjusted R&D expenses are projected to be between $10.5 billion and $11.5 billion, leading to total adjusted expenses of $23.0 billion to $25.0 billion for 2026 [3] - Adjusted diluted EPS for 2026 is anticipated to be in the range of $2.80 to $3.00, reflecting stable gross and operating margins compared to 2025 and a higher effective tax rate [4][5] Comparison of Financial Guidance - The revised 2025 financial guidance includes revenues of approximately $62.0 billion, down from the previous range, with COVID-19 product revenues expected to be around $6.5 billion [5] - Adjusted SI&A expenses for 2025 are projected at $13.1 billion to $14.1 billion, while Adjusted R&D expenses are estimated at $10.0 billion to $11.0 billion [5] - The effective tax rate on adjusted income for 2025 is approximately 11%, compared to an expected 15% for 2026 [5] CEO Commentary - The CEO emphasized that 2025 was a year of strong execution and strategic progress, positioning the company for sustainable growth in the post-loss of exclusivity period [7]

Core Viewpoint - Enbridge Inc. announced its 2026 financial guidance, projecting steady growth driven by new projects and strong utilization of existing assets, alongside a 3% increase in its annual common share dividend [1][2]. Financial Guidance - The company provided 2026 adjusted EBITDA guidance of CAD 20.2 billion to CAD 20.8 billion and distributable cash flow (DCF) per share guidance of CAD 5.70 to CAD 6.10 [1]. - Enbridge reaffirmed its 2025 full-year guidance, expecting to finish in the upper half of the EBITDA range of CAD 19.4 billion to CAD 20.0 billion and at the midpoint for DCF per share [1]. - The company anticipates a compound annual growth rate of 7-9% for EBITDA, 4-6% for adjusted earnings per share (EPS), and approximately 3% for DCF per share from 2023 to 2026 [1]. Dividend Increase - Enbridge declared a 3% increase in its quarterly common share dividend from CAD 0.9425 to CAD 0.97, effective March 1, 2026, marking the 31st consecutive annual increase [1]. Growth Drivers - The projected EBITDA for 2026 is supported by approximately CAD 8 billion of new projects entering service, strong growth from recent rate settlements, and optimization of existing assets [1]. - Key growth drivers include contributions from organic projects, increased rates on U.S. Gas Transmission assets, and favorable re-contracting [1]. Capital Investments and Financing - Enbridge plans to deploy approximately CAD 10 billion of growth capital in 2026, with a strong balance sheet and a debt-to-EBITDA ratio expected to remain within the target range of 4.5-5.0x [1]. - The financing plan includes CAD 10 billion of debt issuances, primarily for refinancing CAD 5 billion of debt maturities, with no external equity required [1].

Financial advisor and financial planner roles are both very broad categories. Know the differences when you're looking for professional financial guidance. https://t.co/dOiIoAFm0V ...

Core Insights - Shake Shack's CFO, Katherine Fogertey, will leave the company on March 4, 2026, transitioning to a senior advisor role immediately to assist in the handover process [1] - The company is initiating a search for a new CFO and has established an Office of the CFO to ensure stability during the transition [2][3] - Shake Shack has reiterated its financial guidance for Q4 2025 and the full year, projecting total revenue growth of 16% year-on-year for 2025 [4][5][6] Financial Guidance - For Q4 2025, Shake Shack forecasts total revenue between $406 million and $412 million, with licensing revenue expected to be between $15.4 million and $15.7 million [5] - Same-Shack sales are anticipated to increase by a low single-digit percentage compared to the same period last year [5] - For the full year 2025, total revenue is projected at approximately $1.45 billion, with licensing revenue expected between $54.1 million and $54.5 million [5][6] Strategic Goals - The company maintains its guidance for adjusted earnings before interest, taxation, depreciation, and amortization (EBITDA) in the range of $210 million to $215 million for fiscal year 2025 [6] - Shake Shack's three-year targets remain unchanged, aiming for total revenue growth and system-wide unit expansion in the low-teens percentage range [6]